Athena Diagnostics News Today

Not surprisingly, the Federal Circuit visited upon Plaintiff/Appellant PureCircle two of the Four Horsemen of the Biotech Patent Apocalypse* in a decision affirming the District Court's...

In view of the unprecedented uncertainty in patent law generated by counter-doctrinal Supreme Court decisions over the past decade or so and a cowed Federal Circuit relegated to...

/PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today announced the availability of the AD-Detect™ Test for...

Whole genome scans took longer than a commercially available test, but not for most urgent cases

Einstein's aphorism that doing the same thing over and over again and expecting a different outcome is a hallmark of madness (or at least an inability to learn from the past) inevitably...

/PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the worlds leading provider of diagnostic information services, today announced nationwide availability of the...

"Hope springs eternal [in the human breast]" (Alexander Pope) and "Insanity is doing the same thing over and over and expecting different results" (the latter attributed variably to...

In CareDx, Inc. v. Natera, Inc., Court of Appeals for the Federal Circuit held CareDx’s patent claims to methods of detecting organ transplant rejection were invalid as patent ineligible under 35 U.S.C. section 101. Claims to medical diagnostics face unique challenges.

DPS Parmar of LexOrbis examines the patentability of diagnostic methods in India and highlights the uncertainty caused by inconsistent application of the rules, confusion over exceptions, and a paucity of judicial interpretation

Growing preference for medicine is expected to provide lucrative opportunities for expansion of applied neurological biomarkers in Alzheimers and Parkinsons